

**To:** (10)(2e) (10)(2e) (10)(2e) @rivm.nl; (10)(2e) (10)(2e) (10)(2e) @rivm.nl  
**From:** (10)(2e)  
**Sent:** Thur 7/16/2020 8:53:13 AM  
**Subject:** RE: epiet covid case study  
**Received:** Thur 7/16/2020 8:53:14 AM

Bedankt, (10)(2e)

(10)(2e) dit is denk ik het meest relevante stukje voor ons:

Potential target groups

1. Elderly and immunocompromised: highest risk, but we may lack evidence on whether this vaccine will produce adequate immune response
2. Health care workers: high risk; mostly healthy adults so appropriate population for new vaccine. Considerations include need to maintain PPE and other infection control measures. What about non-licensed and private caregivers in elderly residences?
3. Children: lack evidence on whether this vaccine is effective in children. COVID19 transmission among children may not be a major factor in transmission (but this might change....)
4. Other essential workers and first responders
5. Other adults (teachers? Adults who reside with or care for frail elderly? Other adults in a vulnerable group?)

Deze groepen moeten we in ieder geval bespreken maar dat hadden we ook al (grotendeels) bedacht.

Groeten, (10)(2e)

-----Original Message-----

**From:** (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>  
**Sent:** donderdag 16 juli 2020 10:20  
**To:** (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>  
**Subject:** FW: epiet covid case study

Ter info

(10)(2e)

-----Original Message-----

**From:** (10)(2e) (10)(2e)  
**Sent:** woensdag 24 juni 2020 09:35  
**To:** (10)(2e) <(10)(2e)@rivm.nl>  
**Subject:** epiet covid case study

Hoi (10)(2e) - dit ter info!

(10)(2e)